



COMMITTEE

CAROLYN H. ASBURY, PH.D.
Chair, NORD Board of Directors

FRANK BALDINO, JR., PH.D.
Chairman & CEO, Cephalon, Inc.

SOL J. BARER, PH.D.
Chairman & CEO, Celgene Corporation

LEONARD BELL, M.D.
CEO, Alexion Pharmaceuticals, Inc.

ALAN BENNETT
Partner, Ropes & Gray

PAMELA BENNETT
Executive Director, Purdue Pharma LP

KIM BERNSTEIN
Director, Access Program,
Accredo Health Group, Inc.

TRICIA BROOKS
Managing Director,
Biotechnology Industry Organization

RON COHEN, M.D.
President & CEO, Acorda Therapeutics

JOSEPH P. COOPER
Executive Vice President, Medicis
Pharmaceutical Corp.

TIMOTHY R. COTÉ, M.D., M.P.H.
Director, Office of Orphan Products
Development, FDA

JOHN F. CROWLEY
President & CEO, Amicus Therapeutics

TIMOTHY DELAPP
Vice President,
Global Movement Disorders, Medtronic, Inc.

LARRY DOWNEY
CEO, Teva Neuroscience, Inc.

MILTON H. ELLIS
President, Rare Disease Therapeutics, Inc.

PATTI ENGEL
President & CEO, Engage Health, Inc.

STEVEN R. FITZPATRICK
President, Accredo Health Group

WILBUR H. GANTZ
Executive Chairman of the Board,
Ovation Pharmaceuticals, Inc.

W. BRADFORD GARY
Vice President,
Government Operations, Allergan, Inc.

ERIC GERVAIS
Executive Vice President, Duchesnay, Inc.

KENNETH R. GREATHOUSE
President, Argent Development Group, LLC

STEPHEN C. GROFT, PHARM.D. Director,
Office of Rare Diseases Research, NIH

STEVEN GROSSMAN
President, HPS Group LLC

WILLIAM R. GUNNARSSON
Board of Directors, Recordati

MARLENE E. HAFFNER, M.D., M.P.H.
Executive Director, Amgen, Inc.

BO JESPER HANSEN
CEO & President,
Swedish Orphan International AB

NANCY HARRIS
Consultant, Harris Consulting

PETER BARTON HUTT
Covington & Burling

EMIL D. KAKKIS, M.D., PH.D.
Chief Medical Officer,
BioMarin Pharmaceutical, Inc.

MARK KRUEGER, M.P.H.
President, Mark Krueger & Associates, Inc.

RICHARD LABAUDINIÈRE, PH.D.
President & CEO,
FoldRx Pharmaceuticals, Inc.

GREGG LAPOINTE
CEO, Sigma-Tau Pharmaceuticals, Inc.

JONATHAN LEWIS, M.D., PH.D.
CEO & Chief Medical Officer,
ZIOPHARM Oncology, Inc.

WAYNE PINES
President, APCO Worldwide

DAVID E.J. PYOTT
Chairman & CEO, Allergan, Inc.

FRANK J. SASINOWSKI
Hyman, Phelps & McNamara, P.C.

BERT SPILKER, M.D., PH.D.
President, Bert Spilker & Associates, LLC

RUTH SUTER
Director, Patient Services,
BioMarin Pharmaceutical, Inc.

HENRI TERMEER
Chairman, President & CEO,
Genzyme Corporation

SUSAN ZASOSKI
Group Vice President,
Accredo Health Group, Inc.

Put simply, NORD provides a safety net for people with rare diseases for whom there is no other source of help.

This year's Gala is at the National Press Club, part of Washington life for nearly 100 years. It will provide the perfect backdrop for this important gathering of thought leaders in healthcare policy; scientific research; and the biotechnology, pharmaceutical, and medical device industries.

I ask that you reply no later than April 20 so that we can recognize your support.

Your support will help us create a world in which those living with serious and life-threatening diseases will have hope for a better future.

Sincerely,

Peter L. Saltonstall
President and CEO